目的 探討抑癌基因Ras相關(guān)區(qū)域家族1A (RASSF1A)基因在結(jié)腸癌組織以及相應(yīng)正常結(jié)腸組織中的表達(dá)并分析其表達(dá)與結(jié)腸癌臨床病理因素之間的關(guān)系。
方法 采用免疫組織化學(xué)SP法和Western blot法檢測(cè)34例結(jié)腸癌手術(shù)標(biāo)本和相應(yīng)的正常結(jié)腸組織中RASSF1A蛋白的表達(dá)水平,應(yīng)用RT-PCR法檢測(cè)RASSF1AmRNA在結(jié)腸癌和正常結(jié)腸組織中的表達(dá)情況。
結(jié)果 ?、倜庖呓M織化學(xué)法結(jié)果:結(jié)腸癌組織中RASSF1A蛋白表達(dá)陽(yáng)性率明顯低于其在正常結(jié)腸組織中的表達(dá)陽(yáng)性率 〔35.3% (12/34)比97.1% (33/34),P<0.05〕。結(jié)腸癌組織中
RASSF1A蛋白的表達(dá)與腫瘤分化程度和TNM分期均有關(guān)(P<0.05),即高、中分化及TNM分期較低(Ⅰ+Ⅱ期)者的RASSF1A蛋白表達(dá)陽(yáng)性率較高(P<0.05)。②Western blot法結(jié)果:在34例結(jié)腸癌患者中RASSF1A蛋白表達(dá)水平明顯低于其在相應(yīng)的正常結(jié)腸組織中的表達(dá)水平 〔0.316 8±0.019 6比0.914 4±0.177 6,P<0.05〕;該結(jié)果與RT-PCR法檢測(cè)到的RASSF1A mRNA表達(dá)情況基本一致 〔0.158 9±0.223 7和0.572 3±0.193 9,P<0.05〕。
結(jié)論 RASSF1A基因的失表達(dá)可能在原發(fā)性結(jié)腸癌的發(fā)生、發(fā)展中起重要作用,檢測(cè)RASSF1A的表達(dá)情況可為結(jié)腸癌的早期診斷提供幫助。
引用本文: 賀賽,孫學(xué)軍,鄭見(jiàn)寶,王煒,周培華,魏光兵,王暉,姚建峰,張立,祿韶英,杜俊凱. 抑癌基因RASSF1A在結(jié)腸癌中的表達(dá)研究△. 中國(guó)普外基礎(chǔ)與臨床雜志, 2013, 20(11): 1240-1244. doi: 復(fù)制
版權(quán)信息: ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
1. | László L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer[J]. Magy Onkol, 2010, 54(4):383-394. |
2. | -9. |
3. | Xiang TX, Yuan Y, Li LL, et al. Aberrant promoter CpG methyl-ation and its translational applications in breast cancer[J]. Chin J Cancer, 2013, 32(1):12-20. |
4. | Van der Weyden L, Papaspyropoulos A, Poulogiannis G, et al. Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis[J]. Cancer Res, 2012, 72(15):3817-3827. |
5. | Sherwood V, Recino A, Jeffries A, et al. The N-terminal RASSF family:a new group of Ras-association-domain-containing proteins,with emerging links to cancer formation[J]. Biochem J, 2010, 425(2):303-311. |
6. | Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2[J]. J Biol Chem, 2011, 286(8):6253-6261. |
7. | Malpeli G, Amato E, Dandrea M, et al. Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors[J]. BMC Cancer, 2011, 11:351. doi:10. 1186/1471-2407-11-351. |
8. | Tian Y, Hou Y, Zhou X, et al. Tumor suppressor RASSF1A promoter:p53 binding and methylation[J]. PLoS One, 2011, 6(2):e17017. doi:10.1371/journal.pone.0017017. |
9. | Jiang Y, Cui L, Chen WD, et al. The prognostic role of RASSF1Apromoter methylation in breast cancer:a meta-analysis of publisheddata[J]. PLoS One, 2012, 7(5):e36780. doi:10. 1371/journal. pone. 0036780. |
10. | 楊雷, 孫學(xué)軍, 王煒, 等. MCP-1、VEGF在胃癌中的表達(dá)與幽門(mén)螺旋桿菌感染的關(guān)系[J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2009,. |
11. | 鄭見(jiàn)寶, 孫學(xué)軍, 王煒, 等. HIF-1α與CDX2在結(jié)直腸腺癌組織中的表達(dá)及意義[J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2012, 17(12):1265-1269. |
12. | Zheng J, Sun X, Wang W, et al. Hypoxia-inducible factor-1alphamodulates the down-regulation of the homeodomain protein CDX2in colorectal cancer[J]. Oncol Rep, 2010, 24(1):97-104. |
13. | Wang W, Sun X, Lu L, et al. Cytotoxicity of lymphocytes activ-ated by superantigen toxic-shock-syndrome toxin-1 against colorectal cancer LoVo cells[J]. Mol Cell Biochem, 2013, 376(1-2):. |
14. | Saelee P, Wongkham S, Chariyalertsak S, et al. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2010, 11(6):1677-1681. |
15. | Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour supp-ressor locus 3p21.3[J]. Nat Genet, 2000, 25(3):315-319. |
16. | Montenegro MF, Sáez-Ayala M, Piñero-Madrona A, et al. Reac-tivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation[J]. PLoS One, 2012, 7(12):e52231. doi:10.1371/journal.pone.0052231. |
17. | (5):375-378. |
18. | Park Y, Kim DS, Park KH, et al. RASSF1A and ERCC1 expre-ssion levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin[J]. Onkologie, 2012, 35(11):673-682. |
19. | Lin HH, Ke HL, Huang SP, et al. Increase sensitivity in detectingsuperficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine[J]. Urol Oncol, 2010, 28(6):597-602. |
20. | Martins AT, Monteiro P, Ramalho-Carvalho J, et al. High RASSF1A promoter methylation levels are predictive of poor prog-nosis in fine-needle aspirate washings of breast cancer lesions[J]. Breast Cancer Res Treat, 2011, 129(1):1-9. |
21. | Ghazaleh HA, Chow RS, Choo SL, et al. 14-3-3 mediated regulation of the tumor suppressor protein, RASSF1A[J]. Apoptosis,. |
22. | Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer;from epigenetic silencing to functional characterization[J]. Biochim Biophys Acta, 2009, 1796(2):114-128. |
23. | 顧全凱, 閆慶輝, 王鳳安, 等. TIMP-3和RASSF1A在大腸癌中的表達(dá)及臨床意義[J]. 世界華人消化雜志, 2012, 20(27):2642-2647. |
24. | Thaler S, Hähnel PS, Schad A, et al. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt[J]. Cancer Res, 2009, 69(5):1748-1757. |
25. | Gordon M, Baksh S. RASSF1A:Not a prototypical Ras effector[J]. Small GTPases, 2011, 2(3):148-157. |
26. | , 15(2):117-127. |
- 1. László L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer[J]. Magy Onkol, 2010, 54(4):383-394.
- 2. -9.
- 3. Xiang TX, Yuan Y, Li LL, et al. Aberrant promoter CpG methyl-ation and its translational applications in breast cancer[J]. Chin J Cancer, 2013, 32(1):12-20.
- 4. Van der Weyden L, Papaspyropoulos A, Poulogiannis G, et al. Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis[J]. Cancer Res, 2012, 72(15):3817-3827.
- 5. Sherwood V, Recino A, Jeffries A, et al. The N-terminal RASSF family:a new group of Ras-association-domain-containing proteins,with emerging links to cancer formation[J]. Biochem J, 2010, 425(2):303-311.
- 6. Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2[J]. J Biol Chem, 2011, 286(8):6253-6261.
- 7. Malpeli G, Amato E, Dandrea M, et al. Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors[J]. BMC Cancer, 2011, 11:351. doi:10. 1186/1471-2407-11-351.
- 8. Tian Y, Hou Y, Zhou X, et al. Tumor suppressor RASSF1A promoter:p53 binding and methylation[J]. PLoS One, 2011, 6(2):e17017. doi:10.1371/journal.pone.0017017.
- 9. Jiang Y, Cui L, Chen WD, et al. The prognostic role of RASSF1Apromoter methylation in breast cancer:a meta-analysis of publisheddata[J]. PLoS One, 2012, 7(5):e36780. doi:10. 1371/journal. pone. 0036780.
- 10. 楊雷, 孫學(xué)軍, 王煒, 等. MCP-1、VEGF在胃癌中的表達(dá)與幽門(mén)螺旋桿菌感染的關(guān)系[J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2009,.
- 11. 鄭見(jiàn)寶, 孫學(xué)軍, 王煒, 等. HIF-1α與CDX2在結(jié)直腸腺癌組織中的表達(dá)及意義[J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2012, 17(12):1265-1269.
- 12. Zheng J, Sun X, Wang W, et al. Hypoxia-inducible factor-1alphamodulates the down-regulation of the homeodomain protein CDX2in colorectal cancer[J]. Oncol Rep, 2010, 24(1):97-104.
- 13. Wang W, Sun X, Lu L, et al. Cytotoxicity of lymphocytes activ-ated by superantigen toxic-shock-syndrome toxin-1 against colorectal cancer LoVo cells[J]. Mol Cell Biochem, 2013, 376(1-2):.
- 14. Saelee P, Wongkham S, Chariyalertsak S, et al. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2010, 11(6):1677-1681.
- 15. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour supp-ressor locus 3p21.3[J]. Nat Genet, 2000, 25(3):315-319.
- 16. Montenegro MF, Sáez-Ayala M, Piñero-Madrona A, et al. Reac-tivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation[J]. PLoS One, 2012, 7(12):e52231. doi:10.1371/journal.pone.0052231.
- 17. (5):375-378.
- 18. Park Y, Kim DS, Park KH, et al. RASSF1A and ERCC1 expre-ssion levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin[J]. Onkologie, 2012, 35(11):673-682.
- 19. Lin HH, Ke HL, Huang SP, et al. Increase sensitivity in detectingsuperficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine[J]. Urol Oncol, 2010, 28(6):597-602.
- 20. Martins AT, Monteiro P, Ramalho-Carvalho J, et al. High RASSF1A promoter methylation levels are predictive of poor prog-nosis in fine-needle aspirate washings of breast cancer lesions[J]. Breast Cancer Res Treat, 2011, 129(1):1-9.
- 21. Ghazaleh HA, Chow RS, Choo SL, et al. 14-3-3 mediated regulation of the tumor suppressor protein, RASSF1A[J]. Apoptosis,.
- 22. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer;from epigenetic silencing to functional characterization[J]. Biochim Biophys Acta, 2009, 1796(2):114-128.
- 23. 顧全凱, 閆慶輝, 王鳳安, 等. TIMP-3和RASSF1A在大腸癌中的表達(dá)及臨床意義[J]. 世界華人消化雜志, 2012, 20(27):2642-2647.
- 24. Thaler S, Hähnel PS, Schad A, et al. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt[J]. Cancer Res, 2009, 69(5):1748-1757.
- 25. Gordon M, Baksh S. RASSF1A:Not a prototypical Ras effector[J]. Small GTPases, 2011, 2(3):148-157.
- 26. , 15(2):117-127.